1. Bernard Escudier is Head of the French Group of Immunotherapy, and Chairman of the GU Tumor Board in Gustave Roussy Institute (Villejuif, France). His main fields of interest are renal cell carcinoma, immunotherapy (cytokines and vaccine) and the development of new strategies (antiangiogenic drugs and gene therapy). He has been largely involved in the development of new targeted therapies for renal cell carcinoma.
2. Camillo Porta is a senior staff member of the Unit of Medical Oncology at the IRCCS San Matteo University Hospital Foundation in Pavia, Italy, and Adjunct Professor of Medical Oncology at the School of Biotechnology and the Postgraduate Schools of Medical Oncology and General Surgery at the University of Pavia. After specializing in medical oncology with honors at the University of Pavia, he undertook an Oncology Research Fellowship at the IRCCS San Matteo University Hospital Foundation. His clinical...